Abstract:Evidence indicated that the x gene of human HBV can cause cancer in transgenic mice; moreover, HBxAg was so far the most frequent and strong antigen among those HBV markers expressed in hepatocellular carcinoma (HCC) tissues. Aimed to enhance killing of HCC by effector cells, we established an anti-HBx/anti-CD3 hybrid-hybridoma by fusion of anti-HBx hybridoma cells with FITC-labelled anti-CD3 HAT sensitive cells, and followed by FACStar sterile cell sorting, HAT selection and eventually verified by ELISA and double binding assay. Application of this bispecific monoclonal antibody (BsAb) is in vitro effector: target cell conjugate assay by using two color cytometric analysis, we found that anti-HBx/anti-CD3 BsAb significantly enhanced the effector : target cell conjugate formation. In in vivo study, BsAb retargetting effector cells were more effective than that of effector cells alone in shrinkage of HCC xenografts in nude mice, not only in freshly inoculated tumors but also in established growing tumors (p < 0.01, p < 0.01). Besides, the apoptotic cells detected by in situ end-labelling technique were remarkable in tissues treated by BsAb plus effector cells. Pronounced infiltration of lymphocytes in the peripheral of tumor nodules can also be seen in the tissues treated by BsAb plus effector cells, but not in the controls. The results indicate that shrinkage of tumors in nude mice with therapy of BsAb retargetting effector cells was partly by initiation of apoptotic cell death in HCC cells.

Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice